Skip to main content
OpenTrials
Completed

NCT Number: NCT04038021

Phosphatidylethanol-Based Contingency Management for Housing

The investigators will evaluate the efficacy of contingency management (CM) in reducing alcohol use in individuals experiencing unstable housing but who are currently housed in shelters. Participants will be 20-30 adults diagnosed with alcohol use disorder (AUD) and has a history or unstable housing or literal homelessness in the last year but is currently receiving housing through Catholic Charities Spokane or other locations. Individuals who demonstrate AUD and have measurable PEth >ng/mL at the baseline visit will be randomized to receive Phosphatidylethanol-based CM treatment or non-contigent treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Alcohol Use Disorder Alcohol-Related Disorders Alcoholism Chemically-Induced Disorders Mental Disorders Substance-Related Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Catholic Charities of Eastern Washington

Spokane, Washington, 99202, United States

About this study

The objective of this study is to determine whether CM intervention improves outcomes in the unstably housed population using alcohol biomarker phosphatidylethanol (PEth) and ethyl glucuronide (EtG) to test alcohol abstinence. In CM, participants receive tangible rewards for demonstrating drug abstinence while non-contingent intervention receive the rewards regardless of PEth and EtG results for alcohol.

The investigators propose to examine whether CM intervention, to reduce alcohol use to abstinence, is a feasible and acceptable treatment in supported housing. Additionally, this study will assess group differences (between PEth-based CM and non-contingent control) in alcohol abstinence, as assessed by PEth, EtG, and self-report. Characterization of group differences in housing status and other alcohol associated harms (e.g., physical and mental health, medical care, and incarceration) will also be analyzed.

A total of 20-30 participants receiving treatment as usual through Catholic Charities Spokane or other locations in the Pacific and Mountain Time Zones will take part. Participants with AUD and have PEth biomarker results above >20 ng/mL, which indicates regular alcohol usage will be randomized to

  • 6 months of PEth-based CM for submitting alcohol-abstinent PEth results of 16:0/18:1 which is associated with abstinence in the past week, which is <20 ng/ml PEth biomarker in the blood when abstinent for 14-28 days. Urine EtG results will be analyzed to verify PEth result findings,
  • 6 months of non-contingent control for submitting samples each week for the first 4 weeks then every 2 weeks for 4 weeks and then every 4 weeks until week 26. Control participants receive reinforcers regardless of the results of their PEth results. The primary outcomes will assess acceptability measured by attrition, Client Satisfaction Questionnaire-8 and qualitative interviews at weeks 4, 12, and 26. Other primary outcomes include assessment of the effectiveness of PEth-based CM on reducing alcohol use to abstinence and housing status.

The investigators will also be examining group differences in secondary outcomes including self-reported abstinence and heavy drinking assessed by the alcohol timeline follow back and urine EtG analyses. Other secondary outcomes include a) Addiction Severity Index Lite which assesses impact of alcohol us on psychiatric, legal, medical and family functioning, b) self-reported drug use and its severity.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Two heavy drinking episodes (Assigned Male at Birth > 4 standard drinks (SDs), Assigned Female at Birth > 3 SDs) in the prior 14 days OR >14 drinks in the past 2 weeks, confirmed by a PEth level >=20 ng/ml
  • DSM-5 diagnosis of a current Alcohol Use Disorder (AUD) as assessed by the Structured Clinical Interview for Diagnostic and Statistical Manual 5 (DSM-5);
  • Age >=18 years;
  • Currently housed at Catholic Charities Spokane or other locations in the Pacific and Mountain time zones; and
  • Previously, literally homeless or unstably housed (e.g., couch surfing) for > 1 month

Exclusion criteria

  • Current diagnosis of substance use disorder (other than AUD and tobacco), severe;
  • Inability to provide informed consent based on the MacArthur Competence Assessment Tool for Clinical Research (MacCAT-CR) and/or age over 65 and Inability to provide informed consent based on the mini-Montreal Cognitive Assessment (mini-MoCA);
  • Alcohol withdrawal-related seizure or hospitalization in prior 12 months; and
  • Psychiatrically or medically unsafe to participate, as assessed by the PI.

Treatment and study plan

Phosphatidylethanol-based Contingency Management

Behavioral

In CM, tangible reinforcers are provided after individuals demonstrate biochemically verified abstinence of various substances. CM is associated with increased abstinence from illicit drugs, nicotine, and alcohol and is the most powerful psychosocial treatment for initiating abstinence of these substances. When participants submit a negative result for alcohol (via blood phosphatidylethanol biomarkers), the subject will receive rewards (gift cards). In contrast, they will not receive rewards when their samples test positive for alcohol.

Other names: Contingency Management (CM)

Non-contingent control

Behavioral

In the non-contingent control intervention, participants will receive rewards (gift cards) regardless of the alcohol biomarker results in their samples. Once the samples have been received, the subjects will receive reinforcers that is consistent with the average from the CM group's earnings.

Primary outcomes

  1. Rate of Attrition to measure acceptability of PEth-based CM Intervention

    Time frame: 26 weeks of treatment (repeated measure) through study completion

    Tolerability of PEth-based CM procedures (pinprick blood sample) measured by attendance, or attrition, with CM noted as acceptable if attrition is less than or equal to 30%. Attrition will be defined as 1 month of no contact with study team.

  2. Acceptability of PEth-based CM: Client Satisfaction Questionnaire-8

    Time frame: Weeks 4, 8, 12, 16, 20, and 26; repeated measure to assess change in satisfaction through study completion

    Administration of Client Satisfaction Questionnaire-8, a brief measure of client satisfaction that has been validated in addiction treatment. The scale ranges from 1 to 4 with 4 indicating higher satisfaction. Total scores therefore range from 8 (least satisfaction) to 32 (highest satisfaction).

  3. Qualitative interviews to assess satisfaction, feasibility and acceptability of PEth-based CM Intervention using Theory Domains Framework (TDF)

    Time frame: Weeks 4, 12, and 26; repeated measure to assess change in satisfaction, feasibility, and tolerability through study completion

    Assessed by TDF to encode interviews to provide comprehensive, theory-informed data to identify determinants of satisfaction, feasibility and acceptability of intervention

  4. Incidence of alcohol abstinence assessed by PEth biomarker

    Time frame: Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, and 26; repeated measure to assess change through study completion

    Efficacy of PEth-based CM in reduction of alcohol consumption to abstinence assessed by measurement of PEth in blood samples. PEth biomarker assessed at 16:0/18:1 for 7 days or < 20 ng/ml which is consistent with 14-28 days of abstinence

  5. Efficacy of PEth-based CM in Stabilization of Housing Status

    Time frame: Weeks 1, 4, 8, 12, 16, 20, and 26; repeated measure to assess change of housing through study completion

    Measured by self-report of housing status using the Residential Timeline Follow Back; includes number of days stably housed, temporarily housed, institutionally housed or literally homeless. Residential Timeline Follow Back classifies location description of housing into literal homelessness, institutional housing, temporary housing, or stable housing.

Secondary outcomes

  1. Self-Reported Alcohol Usage

    Time frame: 26 weeks of treatment (repeated measure) through study completion

    Days self-reported abstinence, drinking or heavy drinking measured by the Alcohol Timeline Follow Back

  2. Alcohol Usage as measured by Urine Ethyl Glucuronide (uEtG)

    Time frame: 26 weeks of treatment (repeated measure) through study completion

    uEtG collected and measured to determine alcohol usage in last 1-4 days; uEtG greater or equal to 300 ng/ml is identified as recent drinking occurrence

  3. The Addiction Severity Index Lite

    Time frame: Weeks 1, 4, 8, 12, 16, 20, and 26 (repeated measure) through study completion

    Assesses alcohol use on psychiatry, legal, medical, and family functioning, as well as self-reported drug use and its severity. Scale ranges from 0 (no craving at all) to 4 (extreme cravings)

Other outcomes

  1. Short-Form Health Survey-12

    Time frame: Weeks 4, 8, 12, 16, 20, and 26 (repeated measure) through study completion

    Measures mental and physical functioning and overall health-related quality of life. The scale for health includes: poor, fair, good, very good, and excellent. The pain interference scale includes: not at all, a little bit, moderately, quite a bit, and extremely.

  2. Non-Study Resource Form for Medical and Criminal Justice Utilization

    Time frame: Weeks 4, 8, 12, 16, 20, and 26 through study completion

    Measures outpatient addiction, mental health, primary care, and vocational services, as well as the emergency department, inpatient psychiatric, and medical hospitalizations, detox admissions, residential addiction treatment, arrests and incarcerations.

  3. Substance Use Test

    Time frame: 26 weeks of treatment (repeated measure) through study completion

    Urine samples will be tested for opioids, amphetamine, methamphetamine, cocaine, and cannabis with E-Z split (type of urine analysis cup) point-of-care immunoassays

  4. Cigarette Consumption

    Time frame: 26 weeks of treatment (repeated measure) through study completion

    Assessed with the Cigarette Timeline Follow Back to measure smoking and other nicotine use

  5. Cognitive Functioning

    Time frame: Week 1 and 26 (repeated measure) through study completion

    Using a battery of cognitive tests from Test My Brain

  6. Fagerstrom Test for Nicotine Dependence

    Time frame: 26 weeks of treatment (repeated measure) through study completion

    Assesses an individual's dependence on nicotine; score total range from 0 to 10 with 0 being no dependence and 10 being most intense physical dependence on nicotine

  7. Alcohol-Related Incentive Salience

    Time frame: Weeks 1, 4, 8, 12, 16, 20, and 26 (repeated measure) through study completion

    Self-rating instrument that provides a total and two subscale scores that measure some cognitive aspects of alcohol cravings

  8. Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES)

    Time frame: Weeks 1, 4, 8, 12, 16, 20, and 26 (repeated measure) through study completion

    19-item scale measuring an individual's eagerness to change drinking habits; each item has a score of 1 (strongly disagree) , 2 (disagree), 3 (not sure/undecided), 4 (agree), and 5 (strongly agree). There are three sub-scales for recognition, ambivalence, and taking steps in relation to drinking. The higher the score for each sub-scale indicate acknowledgement of drinking problem, uncertainty of control over drinking, and changing habits around drinking, respectively. Lower scores indicate denial of alcohol being a problem, not wondering about control of drinking, and not taking steps to change drinking, respectively.

  9. Rate of Adverse Events

    Time frame: 26 weeks of treatment (repeated measure) through study completion

    Risks related to suicidality, dangerous alcohol use and withdrawal symptoms will be assessed

  10. Emotional Functioning - Depression

    Time frame: Weeks 1, 4, 8, 12, 16, 20, and 26 (repeated measure) through study completion

    A questionnaire measuring the severity of depression (PHQ-9). PQQ-9 is scored on a 4 point scale: 1 (not at all), 2 (several days), 3 (more than half the days), and 4 (nearly every day).

  11. Emotional Functioning - Anxiety

    Time frame: Weeks 1, 4, 8, 12, 16, 20, and 26 (repeated measure) through study completion

    A questionnaire measuring the severity of anxiety (GAD-7). GAD-7 is scored on a 4 point scale: 1 (not at all), 2 (several days), 3 (more than half the days), and 4 (nearly every day).

  12. Emotional Functioning - Stress

    Time frame: Weeks 1, 4, 8, 12, 16, 20, and 26 (repeated measure) through study completion

    A questionnaire measuring the severity of stress (PSS). The PSS is scored on a 5 point scale: 0 (Never), 1 (Almost Never), 2 (Sometimes), 3 (Fairly Often), 4 (Very Often)

Sponsors and collaborators

Lead sponsor

Washington State University

Other

Collaborators

  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Registry information

Official study title

Phosphatidylethanol-Based Contingency Management to Reduce Alcohol Use and Improve Housing Outcomes

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Jul 30, 2019
Registry last updated
Apr 27, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.